Moreover, we demonstrated that upregulation of miR-96 in breast cancer cells led to the downregulation of cyclin-dependent kinase (CDK) inhibitors, p27Kip1 and p21Cip1, and upregulation of the cell-cycle regulator cyclin D1 through downregulation of FOXO3a via directly targeting the 3′-UTR of FOXO3a. This evidence concerns the gene FOXO3 and breast carcinoma.